Actinogen Medical (ASX: ACW)

Last close As at 17/07/2024

AUD0.09

0.01 (12.99%)

Market capitalisation

AUD208m

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb portion of the XanaMIA trial will be key for validating the encouraging Xanamem data shown to date. The XanaCIDD study may also validate the drug’s potential for treating CI related to major depressive disorder.

Latest Insights

View More

Healthcare | Flash note

Actinogen Medical — Publication of XanADu biomarker analysis

Healthcare | Update

Actinogen Medical — Funding in place through key catalysts

Healthcare | Update

Actinogen Medical — Pressing forward with Xanamem

Actinogen Medical

Sector

Healthcare

Equity Analyst

Pooya Hemami

Analyst - Healthcare

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dr Steven Gourlay

    CEO and MD

  • Michael Roberts

    Head of investor relations

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 200.0 204.2 141.7
Relative 187.0 187.9 118.6
52 week high/low A$0.1/A$0.0

Financials

Actinogen Medical’s lead asset, Xanamem, is a once-daily oral selective 11beta-HSD1 inhibitor, designed to cross the blood-brain barrier and target excess brain cortisol, which has been associated with CI. The company is targeting two CI indications: for patients with mild CI in the early stages of Alzheimer’s disease (AD) and for patients with major depressive disorder. Positive results in healthy adults demonstrated the drug’s initial efficacy, while an analysis of biomarker-positive (pTau-181) patients using plasma samples from the previous XanADu study in mild AD also showed clinical activity using the CDR-SB scale, as published in the June 2024 issue of the Journal of Alzheimer’s Disease. Actinogen dosed the first patient in its Phase IIb XanaMIA trial in patients with biomarker-confirmed early AD in April 2024, and plans to report interim data in mid CY25. It expects to report data from the XanaCIDD Phase II trial in major depressive disorder in early Q3 CY24.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 3.6 (9.1) (7.9) (0.460) N/A N/A
2023A 4.9 (10.6) (8.9) (0.494) N/A N/A
2024E 7.9 (14.7) (14.0) (0.621) N/A N/A
2025E 7.7 (14.0) (13.7) (0.512) N/A N/A

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free